We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Memory Pharmaceuticals has announced the first dosing in a Phase I study of
MEM 3454, a partial agonist of the nicotinic alpha-7 receptor, in healthy
volunteers.
OSI Pharmaceuticals has initiated a Phase I clinical study of OSI-930, the
first drug candidate to emerge from the company's research program focused
on the identification of dual c-kit/vascular endothelial growth factor receptor
(VEGFR) inhibitors.
Genaera has released clinical trial results, including pharmacokinetic data
and updated visual acuity outcomes, from a multicenter, open-label, U.S. Phase
II clinical trial (MSI-1256F-207) with Evizon for the treatment of choroidal
neovascularization associated with age-related macular degeneration (AMD), also
known as "wet" AMD.
Intarcia Therapeutics has initiated its CAT (Combined Anti-estrogen Therapy)
study, a global, randomized Phase III study of combination hormonal therapy
for the first-line treatment of advanced breast cancer.
Amgen has announced that data from the largest randomized, placebo-controlled
study to date for Neulasta has been published in The Journal of Clinical
Oncology.
Medarex expects to receive an undisclosed milestone payment from its licensing
partner, Amgen, for the advancement of an antibody into clinical trials.
Nymox Pharmaceutical's proprietary NXC-4720 product for the treatment of potentially
fatal E. coli O157:H7 contamination is capable of reducing the level of contamination
on fresh beef by 99 percent, according to laboratory studies.
Novo Nordisk has announced the results of a recently completed clinical trial
of NovoSeven Coagulation Factor VIIa (recombinant) in patients with acute
intracerebral hemorrhage (ICH) as published in The New England Journal
of Medicine (NEJM).